Evidence map›Paper›PMID 39528509›Full record

ArticleScientific reports2024

Primate-specific 82-kDa choline acetyltransferase attenuates progression of Alzheimer's disease-like pathology in the APP

Hadir E AlQot, Rebecca Jane Rylett

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hadir E AlQotDepartment of Physiology and Pharmacology, Schulich School of Medicine & Dentistry, Robarts Research Institute, University of Western Ontario, London, ON, N6A 5K8, Canada.
Rebecca Jane RylettDepartment of Physiology and Pharmacology, Schulich School of Medicine & Dentistry, Robarts Research Institute, University of Western Ontario, London, ON, N6A 5K8, Canada. jane.rylett@schulich.uwo.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is characterized by amyloidosis, neuroinflammation, cholinergic dysfunction and cognitive impairment. In AD, the cholinergic neuronal marker choline acetyltransferase (ChAT) is reduced and the primate-specific nuclear isoform, 82-kDa ChAT, is mislocalized to cytoplasm. Cell-based studies suggest a role for 82-kDa ChAT in regulating expression of AD-related genes with potential reductions in β-amyloid (Aβ) levels. To study this further, we crossed transgenic mice expressing human 82-kDa ChAT with the AD mouse model APP

Indexed as

Alzheimer DiseaseCholine O-AcetyltransferaseDisease Models, AnimalMice, TransgenicAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAnimalsCognitive DysfunctionDisease ProgressionGene Knock-In TechniquesHumansMaleMiceNeuronsPlaque, AmyloidPrimatesAmyloid beta-PeptidesAmyloid beta-Protein PrecursorCholine O-Acetyltransferase82-kDa choline acetyltransferaseAlzheimer’s diseaseAPPNL-G-F miceImmunofluorescenceMicrogliaNeurobehavioral testingPCR arrayβ-Amyloid clearance

Identifiers

PMID39528509
PMCPMC11555257

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.